Umpierrez, Guillermo E. http://orcid.org/0000-0002-3252-5026
Davis, Georgia M. http://orcid.org/0000-0001-9671-0063
ElSayed, Nuha A. http://orcid.org/0000-0003-1217-4916
Fadini, Gian Paolo http://orcid.org/0000-0002-6510-2097
Galindo, Rodolfo J. http://orcid.org/0000-0002-9295-3225
Hirsch, Irl B. http://orcid.org/0000-0003-1675-8417
Klonoff, David C. http://orcid.org/0000-0003-1335-1857
McCoy, Rozalina G. http://orcid.org/0000-0002-2289-3183
Misra, Shivani http://orcid.org/0000-0003-2886-0726
Gabbay, Robert A. http://orcid.org/0000-0003-3541-1486
Bannuru, Raveendhara R. http://orcid.org/0000-0002-8069-5783
Dhatariya, Ketan K. http://orcid.org/0000-0003-3619-9579
Article History
Received: 28 March 2024
Accepted: 29 March 2024
First Online: 22 June 2024
Acknowledgements
: The authors thank R. Aaron and T. Tian (Diabetes Technology Society, Burlingame, CA, USA) for their editing assistance and M. Bonar (Leicester Diabetes Centre, Leicester, UK) for figure design. Parts of this work were presented at: the 59th EASD Annual Meeting, Hamburg, Germany, 2–6 October 2023; the AACE Annual Meeting, New Orleans, LA, USA, 9–11 May 2024; and the ADA 84th Scientific Sessions, Orlando, FL, USA, 21–24 June 2024.
: GEU is supported by research grants from the National Institutes of Health (NIH) (NATS UL 3UL1TR002378-05S2) from the Clinical and Translational Science Award programme and from the NIH and National Center for Research Resources (NIH/National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK] 2P30DK111024-06) and has served as a member of advisory boards for Dexcom and GlyCare. GMD is supported by a research grant from NIH/NIDDK Career Development Award K23DK122199, has received research support from Insulet and has consulted for Medscape. GPF has received honoraria and consultancy and lecture fees from Abbott, AstraZeneca, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk, Mundipharma, Sanofi, Takeda and Servier. RJG is supported by the NIDDK of the NIH under award numbers P30DK111024-08, 1K23DK123384 and 1R03DK138255. RJG has also received research support (to Emory University, Atlanta, GA, USA) for studies from Novo Nordisk, Dexcom and Eli Lilly and consulting/advisory or honoraria/lecture fees from Abbott Diabetes, Dexcom, Eli Lilly, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Medtronic, and Bayer outside of this work. IBH has received research support from the NIH, Dexcom and MannKind and serves as consultant for Abbott Diabetes Care, Embecta and Hagar. DCK is a consultant for Afon, Atropos Health, GlucoTrack, Lifecare, Nevro, Novo Nordisk, Samsung and Thirdwayv. RGM is supported by the NIDDK of the NIH (R03DK127010 and R01DK135515), the National Institute on Aging of the NIH (R01AG079113), the Patient-Centered Outcomes Research Institute (DB-2020C2-20306), and the American Diabetes Association. RGM also serves as a consultant to EmmiEducation (Wolters Kluwer) on developing patient education materials related to diabetes and to Yale New Haven Health System’s Center for Outcomes Research and Evaluation on developing quality measures related to diabetes. SM holds a personal award from the Wellcome Trust Clinical Career Development Scheme (223024/Z/21/Z) and is supported by the National Institute for Health Research Imperial Biomedical Research Centre. SM also reports an investigator-initiated grant from Dexcom and has received speaker fees (donated to the institution) from Sanofi and Lilly. RAG has served as a consultant to Lark, Vida and Sweetch. RRB and NAE declare that there are no relationships or activities that might bias, or be perceived to bias, their work. KKD has received honoraria for travel, advisory boards and speaker fees from Abbott Diabetes, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Eli Lily, Menarini and Sanofi Diabetes. No other potential conflicts of interest relevant to this article were reported.